Latest Content

Adoptive cell therapy elicited MRD-negative responses with low rates of GVHD and neurotoxicities in adult patients with high-risk B-ALL.

The FDA updated axi-cel labeling to remove the limitation of use for patients with relapsed or refractory primary central nervous system lymphoma.

Johannes R. Kratz, MD, has been named as the inaugural Chief of UCSF’s Division of Thoracic Surgery.

OS Therapies began a rolling submission of a BLA for OST-HER2 in fully resected pulmonary metastatic osteosarcoma.

A real-world cilta-cel study revealed a link between high lymphocyte peaks and failed bridging to parkinsonism and nonrelapse mortality, potentially guiding early intervention.

EMA CHMP recommends first-line retifanlimab plus carboplatin/paclitaxel for advanced anal cancer, backed by phase 3 P0D1UM-303 data.

With an additional 16.1 months of follow-up, the dual HER2-targeted, chemotherapy-free regimen maintained efficacy and safety in HER2-positive mCRC.

Orca-T/reduced-intensity conditioning was effective and decreased GVHD incidence vs PTCy/reduced-intensity conditioning in hematologic malignancies.

The FDA issued a reminder to increase awareness regarding updated capecitabine and 5-FU labels to highlight DPD deficiency risks.

Real-world data confirm the importance of tumor debulking with bridging therapy to reduce the risk of parkinsonism and NRM with cilta-cel in myeloma.

Ustekinumab plus prophylaxis did not reduce acute GVHD in patients who underwent HCT from matched unrelated donors.

No serious adverse effects were observed with TRX103 in patients with hematologic malignancies undergoing HLA-mismatched HCT.

The FDA-approved drug abatacept may improve treatment responses and prevent some immune AEs associated with CAR T-cell therapy.